But one thing Dr
NH GI SN PHM
Zufferey R, Dull T, Mandel RJ, et al
nonetheless, the Researching cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial indicated no significant hepatobiliary adverse events in the dulaglutide cohort vs
Eleven brands across six molecules, made almost entirely by two companies Novo Nordisk and Eli Lilly: Semaglutide (Novo Nordisk) Ozempic, Wegovy, Rybelsus Tirzepatide (Eli Lilly) Mounjaro, Zepbound Liraglutide (Novo Nordisk) Victoza, Saxenda Dulaglutide (Eli Lilly) Trulicity Exenatide (AstraZeneca) Byetta, Bydureon BCise Lixisenatide (Sanofi) Adlyxin, no longer marketed in the US For weight management , the FDA has approved Wegovy, Zepbound and Saxenda
It is studied for anti-inflammatory activity, particularly through modulation of the NF-B signaling pathway